*Average 12-month price target from 1 stock analysts.
No financial data available for this stock yet.
Innovate Biopharmaceuticals, Inc.
9 Meters Biopharma operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.